RxDoctor Payments Data

Kamlesh Gosai, MD

Internal Medicine · Bentleyville, PANPI 1033115241

Payments from drug & device makers

$337in general payments, 2019–2025

Across 14 payments — averaging $24.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$110
  • AbbVie$80
  • Novo Nordisk$47
  • Bayer$36
  • Pfizer$23
  • Boehringer Ingelheim$15
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$29989%
  • Education$3811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen1$110
AbbVie(2 entities)6$80
Novo Nordisk2$47
Bayer1$36
Pfizer1$23
Boehringer Ingelheim1$15
Sun Pharmaceutical Industries Inc.1$14
GSK1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$337 in reported general payments places this provider in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$255,125
Medicare patients
313
Services billed
6,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban252$187,269
JardianceEmpagliflozin155$139,128
OzempicSemaglutide111$129,729
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$68,635
MounjaroTirzepatide41$53,266
Tresiba Flextouch U-200Insulin Degludec33$35,018
FarxigaDapagliflozin Propanediol31$31,638
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog33$30,253
TrulicityDulaglutide20$28,589
CreonLipase/Protease/Amylase12$27,923
XareltoRivaroxaban42$27,138
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr33$19,028
JanuviaSitagliptin Phosphate17$16,842
MyrbetriqMirabegron26$16,695
EntrestoSacubitril/Valsartan13$16,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$187,269252 claims
Boehringer IngelheimJardiance$15$139,128155 claims
Novo NordiskOzempic$47$129,729111 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$11$102,332131 claims
AbbVieCreon, Linzess, Synthroid$80$46,35082 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Bentleyville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →